Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Multiple Sclerosis | 20 | 2021 | 2600 | 2.99 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 7 | 2020 | 529 | 1.59 | Why? |
| Social Networking | 2 | 2018 | 737 | 0.91 | Why? |
| Disability Evaluation | 6 | 2020 | 671 | 0.80 | Why? |
| Gait Disorders, Neurologic | 1 | 2019 | 64 | 0.72 | Why? |
| Executive Function | 1 | 2019 | 173 | 0.66 | Why? |
| Sexuality | 1 | 2017 | 85 | 0.63 | Why? |
| Internet | 4 | 2018 | 6204 | 0.50 | Why? |
| Walking | 1 | 2017 | 442 | 0.50 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.45 | Why? |
| Immunologic Factors | 5 | 2020 | 4206 | 0.44 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.39 | Why? |
| Cognitive Reserve | 2 | 2018 | 17 | 0.38 | Why? |
| Telemedicine | 10 | 2021 | 25032 | 0.36 | Why? |
| Physician-Patient Relations | 1 | 2018 | 1266 | 0.35 | Why? |
| Neurology | 4 | 2021 | 1613 | 0.35 | Why? |
| Cognitive Dysfunction | 1 | 2019 | 1389 | 0.33 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.32 | Why? |
| Neuropsychological Tests | 3 | 2019 | 954 | 0.29 | Why? |
| Neuromyelitis Optica | 2 | 2020 | 397 | 0.28 | Why? |
| Disease Progression | 2 | 2019 | 13580 | 0.26 | Why? |
| Adaptation, Psychological | 1 | 2019 | 4996 | 0.22 | Why? |
| Motor Disorders | 1 | 2020 | 45 | 0.21 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.19 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.19 | Why? |
| Mental Processes | 1 | 2018 | 19 | 0.18 | Why? |
| Parasympatholytics | 1 | 2017 | 7 | 0.18 | Why? |
| Biomechanical Phenomena | 1 | 2019 | 291 | 0.18 | Why? |
| Thalamus | 1 | 2018 | 75 | 0.17 | Why? |
| Fingolimod Hydrochloride | 1 | 2019 | 217 | 0.17 | Why? |
| Neuromuscular Diseases | 1 | 2021 | 303 | 0.17 | Why? |
| Translating | 1 | 2017 | 80 | 0.17 | Why? |
| Regression Analysis | 4 | 2018 | 2484 | 0.17 | Why? |
| Stroke Rehabilitation | 1 | 2021 | 299 | 0.17 | Why? |
| Neuralgia | 1 | 2018 | 99 | 0.16 | Why? |
| Rest | 1 | 2017 | 188 | 0.16 | Why? |
| Monitoring, Ambulatory | 1 | 2020 | 343 | 0.16 | Why? |
| Interferon beta-1a | 1 | 2019 | 316 | 0.16 | Why? |
| Nerve Net | 1 | 2017 | 118 | 0.16 | Why? |
| Italy | 10 | 2021 | 38444 | 0.15 | Why? |
| Muscle Spasticity | 1 | 2017 | 117 | 0.15 | Why? |
| Depression | 2 | 2020 | 14116 | 0.15 | Why? |
| Social Media | 1 | 2017 | 5798 | 0.15 | Why? |
| Myasthenia Gravis | 1 | 2021 | 385 | 0.15 | Why? |
| Magnetic Resonance Imaging | 6 | 2019 | 6551 | 0.15 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2020 | 398 | 0.14 | Why? |
| Attention | 1 | 2018 | 335 | 0.14 | Why? |
| Pain Measurement | 1 | 2018 | 533 | 0.14 | Why? |
| Rituximab | 2 | 2019 | 1096 | 0.14 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.13 | Why? |
| Neoplasm Recurrence, Local | 1 | 2021 | 1063 | 0.13 | Why? |
| Brain | 3 | 2018 | 5133 | 0.12 | Why? |
| Humans | 37 | 2021 | 930598 | 0.12 | Why? |
| Organ Size | 3 | 2018 | 384 | 0.11 | Why? |
| Parkinson Disease | 2 | 2020 | 1414 | 0.11 | Why? |
| Wearable Electronic Devices | 1 | 2018 | 694 | 0.11 | Why? |
| Methionine | 1 | 2010 | 53 | 0.11 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.11 | Why? |
| Interpersonal Relations | 1 | 2018 | 926 | 0.10 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.10 | Why? |
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 133 | 0.10 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.10 | Why? |
| Adult | 16 | 2020 | 244371 | 0.10 | Why? |
| Disabled Persons | 1 | 2020 | 1152 | 0.10 | Why? |
| Valine | 1 | 2010 | 359 | 0.09 | Why? |
| Male | 18 | 2020 | 367725 | 0.09 | Why? |
| Female | 18 | 2020 | 380317 | 0.09 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.09 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.09 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.09 | Why? |
| Epilepsy | 1 | 2020 | 1401 | 0.09 | Why? |
| Atrophy | 2 | 2018 | 192 | 0.09 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Middle Aged | 14 | 2020 | 270681 | 0.08 | Why? |
| Dementia | 1 | 2020 | 1861 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Fatigue | 1 | 2017 | 2479 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Social Support | 1 | 2021 | 3183 | 0.08 | Why? |
| Plant Extracts | 1 | 2017 | 1514 | 0.08 | Why? |
| Neuroimaging | 1 | 2013 | 1106 | 0.08 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.07 | Why? |
| Diet | 1 | 2017 | 2052 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.07 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.06 | Why? |
| Attitude to Health | 1 | 2017 | 2002 | 0.06 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
| Cognition Disorders | 2 | 2018 | 574 | 0.06 | Why? |
| Caregivers | 1 | 2017 | 3112 | 0.06 | Why? |
| Nervous System Diseases | 2 | 2018 | 4092 | 0.06 | Why? |
| Registries | 2 | 2019 | 12327 | 0.06 | Why? |
| Levodopa | 1 | 2002 | 87 | 0.06 | Why? |
| Antiparkinson Agents | 1 | 2002 | 125 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Putamen | 1 | 2018 | 24 | 0.05 | Why? |
| Gyrus Cinguli | 1 | 2017 | 28 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Cost Sharing | 1 | 2017 | 39 | 0.04 | Why? |
| Recommended Dietary Allowances | 1 | 2017 | 43 | 0.04 | Why? |
| Cardiovascular Abnormalities | 1 | 2017 | 72 | 0.04 | Why? |
| Stroke | 1 | 2021 | 8839 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2010 | 3607 | 0.04 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.04 | Why? |
| Dronabinol | 1 | 2017 | 89 | 0.04 | Why? |
| Cerebellum | 1 | 2018 | 119 | 0.04 | Why? |
| Fatty Acids, Unsaturated | 1 | 2017 | 70 | 0.04 | Why? |
| Gray Matter | 1 | 2018 | 150 | 0.04 | Why? |
| Aging | 1 | 2013 | 3581 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Neural Pathways | 1 | 2017 | 155 | 0.04 | Why? |
| Brain Mapping | 1 | 2017 | 228 | 0.04 | Why? |
| Body Weight | 1 | 2002 | 1074 | 0.04 | Why? |
| Leptin | 1 | 2017 | 141 | 0.04 | Why? |
| Fatty Acids | 1 | 2017 | 238 | 0.04 | Why? |
| Image Processing, Computer-Assisted | 2 | 2017 | 1383 | 0.04 | Why? |
| Cannabidiol | 1 | 2017 | 138 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2018 | 53120 | 0.04 | Why? |
| Prospective Studies | 2 | 2019 | 43301 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.04 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.03 | Why? |
| Stroke, Lacunar | 1 | 2013 | 20 | 0.03 | Why? |
| Myelin Sheath | 1 | 2013 | 41 | 0.03 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.03 | Why? |
| Complementary Therapies | 1 | 2017 | 280 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Body Composition | 1 | 2017 | 414 | 0.03 | Why? |
| Micronutrients | 1 | 2017 | 310 | 0.03 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.03 | Why? |
| Metabolic Diseases | 1 | 2017 | 505 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Switzerland | 1 | 2019 | 2738 | 0.03 | Why? |
| Information Seeking Behavior | 1 | 2018 | 539 | 0.03 | Why? |
| Osteoporosis | 1 | 2017 | 410 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 317 | 0.03 | Why? |
| Dysbiosis | 1 | 2017 | 685 | 0.03 | Why? |
| Drug Industry | 1 | 2017 | 689 | 0.02 | Why? |
| Young Adult | 5 | 2018 | 93724 | 0.02 | Why? |
| Smartphone | 1 | 2020 | 1840 | 0.02 | Why? |
| DNA Mutational Analysis | 1 | 2010 | 581 | 0.02 | Why? |
| Drug Approval | 1 | 2017 | 1325 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Malnutrition | 1 | 2017 | 932 | 0.02 | Why? |
| Analysis of Variance | 1 | 2010 | 950 | 0.02 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.02 | Why? |
| Health Communication | 1 | 2018 | 1120 | 0.02 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.02 | Why? |
| Gene Frequency | 1 | 2010 | 1210 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Retrospective Studies | 3 | 2019 | 105322 | 0.02 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.01 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Aged | 4 | 2020 | 215776 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Chi-Square Distribution | 1 | 2002 | 961 | 0.01 | Why? |
| Statistics, Nonparametric | 1 | 2002 | 1008 | 0.01 | Why? |
| Genotype | 1 | 2010 | 4697 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Cohort Studies | 2 | 2017 | 36005 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.01 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.01 | Why? |
| Area Under Curve | 1 | 2002 | 2564 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Case-Control Studies | 1 | 2010 | 17671 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2013 | 25144 | 0.00 | Why? |